February 20, 2026 07:46 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
PM Modi warns ‘AI must not control humans’ as India unveils bold tech vision at AI Impact Summit 2026 | Former South Korean President Yoon Suk Yeol sentenced to life over failed martial law bid | Tata Group joins hands with OpenAI in massive AI push to transform India and global industries | Epstein Files row: Bill Gates to skip keynote address at AI Summit 2026 | AI Impact Summit: Google launches game-changing America-India Connect plan with $15 billion backing | AI takes centre stage as Modi meets Google CEO Sundar Pichai in Delhi | G7 Spotlight: Emmanuel Macron invites Narendra Modi for 2026 Summit | AI Summit embarrassment! Galgotias University asked to vacate stall after ‘own robot’ exposed as China’s Unitree Go2 | Actor Rajpal Yadav granted interim bail in ₹9-crore cheque bounce case | Learn AI or become redundant: Microsoft India President issues stark message
AstraZeneca
Pixabay

AstraZeneca's COVID-19 vaccine trial to resume in US

| @indiablooms | Oct 24, 2020, at 03:28 pm

Washington/Xinhua: Multinational pharmaceutical company AstraZeneca said on Friday it will resume the trial of its experimental COVID-19 vaccine in the United States, which has been paused since September.

The company said the U.S. Food and Drug Administration (FDA) authorized the restart of the trial in the United States on Friday, following the resumption of trials in other countries in recent weeks.

The FDA reviewed all safety data from trials globally and concluded it was safe to resume the trial, said the company in a statement.

As part of the standard review process for trial safety events, a voluntary pause to vaccination across all global trials was triggered on Sept. 6 to allow the examination of safety data by independent monitoring committees, according to the company.

The recommendations from these reviews have been supported by international regulators, who also confirmed that the trials were safe to resume, said the statement.

AstraZeneca said results from the late-stage trials are expected later this year.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.